News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Moist wound dressing for chronic wound treatment now available in Germany
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Subscribe To Our Newsletter & Stay Updated
